Towards this aim, we first treated luminal‐type MCF‐7 and T47D breast cancer cells with three HSP90 N‐terminal inhibitors (17‐AAG, AUY922 and STA‐9090) and three HSP90 C‐terminal inhibitors (NB, cisplatin and EGCG) (Figure 1B and Tables S7 and S8).26, 27. This evidence concerns the gene HSP90AB1 and breast carcinoma.